12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vimizim elosulfase alfa regulatory update

BioMarin submitted an MAA to EMA for Vimizim elosulfase alfa to treat mucopolysaccharidosis IVA (MPS-IVA, Morquio's syndrome). In March, BioMarin...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >